Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Pneumococcal Vaccine Market

Pneumococcal Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccines (PCVs), Pneumococcal Polysaccharide Vaccines (PPSVs)), By Technology Platform (Conjugate Vaccine Technology, Polysaccharide Vaccine Technology), By End User (Hospitals, Pediatric Clinics, Adult Vaccination Centers, Public Immunization Programs, Pharmacies / Retail Vaccination), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2025129 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Pneumococcal vaccine market size was valued at $8.90 billion in 2025 and is projected to reach $15.53 billion by 2035, growing at a CAGR of 5.7% between 2026 and 2035. The market consists of vaccines used to prevent infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, and bloodstream infections. These vaccines play a critical role in global immunization programs and public health initiatives. A key driver supporting market growth is the increasing burden of infectious diseases and expansion of vaccination programs worldwide. According to the World Health Organization, pneumonia remains a leading cause of death among children under five, highlighting the importance of preventive vaccines. Additionally, global immunization programs supported by UNICEF are significantly increasing vaccine distribution in low- and middle-income countries. Rising awareness regarding adult vaccination and increasing healthcare expenditure are further strengthening market demand. Pneumococcal vaccines are widely administered across hospitals, pediatric clinics, and public immunization programs, ensuring protection for high-risk populations.

Market Dynamics

Rising Immunization Programs Driving Market Growth

The increasing expansion of global immunization programs is a major factor driving the pneumococcal vaccine market. Governments and international organizations are prioritizing vaccination to reduce disease burden and mortality rates. According to the World Health Organization, immunization prevents millions of deaths annually, demonstrating its critical role in healthcare systems. Pneumococcal vaccines are a key component of these programs, particularly in developing regions. Organizations such as Gavi, the Vaccine Alliance are actively supporting the distribution of pneumococcal conjugate vaccines, enabling large-scale vaccination coverage. Increasing healthcare investments and government initiatives between 2025 and 2026 are accelerating vaccine adoption. Manufacturers are focusing on expanding production capacity and developing advanced vaccines with broader serotype coverage to meet rising demand.

High Development Costs Limiting Market Growth

Despite strong demand, the pneumococcal vaccine market faces challenges related to high development and production costs. Vaccine manufacturing involves complex processes, strict quality control, and extensive clinical trials. According to the U.S. Food and Drug Administration, vaccines must undergo rigorous safety and efficacy testing before approval, increasing development timelines and costs. Additionally, cold-chain logistics and distribution challenges increase operational expenses, particularly in emerging markets. Supply chain disruptions and raw material shortages further impact production efficiency. To address these issues, companies are investing in advanced manufacturing technologies, improving supply chain resilience, and forming strategic partnerships to streamline distribution and reduce costs.

Market Segmentation

  • Based on the Vaccine Type, the market is segmented into Pneumococcal Conjugate Vaccines (PCVs) and Pneumococcal Polysaccharide Vaccines (PPSVs).
  • Based on the Technology Platform, the market is segmented into Conjugate Vaccine Technology and Polysaccharide Vaccine Technology.
  • Based on the End-User Industry, the market is segmented into Hospitals, Pediatric Clinics, Adult Vaccination Centers, Public Immunization Programs, and Pharmacies / Retail Vaccination.

Pneumococcal Conjugate Vaccines (PCVs) Segment Leads the Market

The pneumococcal conjugate vaccines segment holds a dominant position in the pneumococcal vaccine market due to its superior immunogenicity and long-term protection. These vaccines are widely used in pediatric immunization programs and are increasingly adopted for adult vaccination. Growing government initiatives and vaccination campaigns between 2022 and 2026 are driving segment growth. Manufacturers are focusing on developing higher-valency conjugate vaccines to expand coverage and improve effectiveness, strengthening their market presence.

Conjugate Vaccine Technology Segment to Record Strong Growth

The conjugate vaccine technology segment is expected to witness strong growth due to advancements in vaccine development and increasing demand for effective immunization solutions. This technology offers enhanced immune response and long-lasting protection compared to traditional vaccines. Rising investments in research and development and the introduction of innovative vaccine platforms are supporting segment growth. Companies are integrating advanced biotechnological processes to improve vaccine efficacy and scalability.

Regional Outlook

The global pneumococcal vaccine market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the pneumococcal vaccine market due to strong healthcare infrastructure and high vaccination coverage. According to the Centers for Disease Control and Prevention, vaccination programs in the country have significantly reduced the incidence of pneumococcal diseases. Government support, advanced healthcare systems, and strong presence of leading pharmaceutical companies further contribute to market growth.

China to Record Strong Growth

China is expected to witness strong growth due to expanding healthcare infrastructure and increasing vaccination awareness. According to the International Trade Centre, China remains a major hub for pharmaceutical manufacturing and exports. Rising government initiatives and increasing healthcare investments are supporting vaccine adoption across the country.

Competitive Landscape

The pneumococcal vaccine market is highly competitive, characterized by strong focus on innovation and strategic collaborations. Leading companies such as Pfizer Inc., Merck & Co., Inc., GSK plc, Serum Institute of India Pvt. Ltd., and Walvax Biotechnology Co., Ltd. are focusing on expanding product portfolios, enhancing vaccine efficacy, and strengthening global distribution networks to maintain competitive advantage.

Recent Developments

  • In March 2026, Vaxcyte, Inc. (USA) announced the completion of enrolment for its Phase 3 OPUS-1 and OPUS-2 clinical trials evaluating VAX-31, a next-generation 31-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease and pneumonia in adults. The trials include approximately 4,000 participants in OPUS-1 and 1,300 participants in OPUS-2, with the program designed in alignment with the U.S. Food and Drug Administration to support a future Biologics License Application (BLA). This milestone strengthens Vaxcyte’s clinical pipeline and positions VAX-31 as a potential best-in-class vaccine with broader serotype coverage and improved protection.
  • In March 2025, Merck & Co., Inc. (USA / Europe) announced that the European Commission approved CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for adult immunization against invasive pneumococcal disease and pneumonia. The approval, based on Phase 3 STRIDE clinical program data, enables commercialization across all EU member states and selected European countries. This milestone strengthens Merck’s global vaccine portfolio, expands its geographic presence, and enhances protection coverage against multiple pneumococcal serotypes in adult populations.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualised market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global pneumococcal vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Pneumococcal Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User ($ Million)
  • Pneumococcal Vaccine Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Pneumococcal Vaccine Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Pneumococcal Vaccine Market

2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Pneumococcal Vaccine Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Pneumococcal Vaccine Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Pneumococcal Vaccine Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Pneumococcal Vaccine Market Revenue and Share by Manufacturers

  • Pneumococcal Vaccine Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Pfizer Inc.

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Merck & Co., Inc.

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 GSK plc

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Serum Institute of India Pvt. Ltd.
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 Walvax Biotechnology Co., Ltd.
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration

  1. Global Pneumococcal Vaccine Market Sales Analysis by Vaccine Type ($ Million)

5.1 Pneumococcal Conjugate Vaccines (PCVs)

5.2 Pneumococcal Polysaccharide Vaccines (PPSVs)

  1. Global Pneumococcal Vaccine Market Sales Analysis by Technology Platform ($ Million)

6.1 Conjugate Vaccine Technology
6.2 Polysaccharide Vaccine Technology

  1. Global Pneumococcal Vaccine Market Sales Analysis by End User ($ Million)

7.1 Hospitals

7.2 Pediatric Clinics

7.3 Adult Vaccination Centres

7.4 Public Immunisation Programs

7.5 Pharmacies / Retail Vaccination

  1. Regional Analysis

8.1 North American Pneumococcal Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User ($ Million)

8.1.1 United States
8.1.2 Canada

8.2 European Pneumococcal Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User ($ Million)

8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France

8.2.6 Russia
8.2.7 Rest of Europe

8.3 Asia-Pacific Pneumococcal Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User ($ Million)

8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Pneumococcal Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User ($ Million)

8.4.1 Latin America
8.4.2 Middle East and Africa

  1. Company Profiles

9.1 AstraZeneca plc

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2 Beijing Zhifei Lansen Biological Products Co., Ltd.

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3 Bharat Biotech International Ltd.

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4 Biological E. Limited

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5 CanSino Biologics Inc.

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6 China National Biotec Group

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7 Clover Biopharmaceuticals

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8 EuBiologics Co., Ltd.

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.9 Hualan Biological Engineering Inc.

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.10 Inventprise

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies

9.11 KM Biologics Co., Ltd.

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Minhai Biotechnology Co., Ltd.

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Panacea Biotec Ltd.

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 PT Bio Farma

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 Sanofi S.A.

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Sinovac Biotech Ltd.

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 SK Bioscience Co., Ltd.

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies

9.18 Vaxcyte, Inc.

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 Wuxi Biologics

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 Zydus Lifesciences Ltd.

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Pneumococcal Vaccine Market Research and Analysis by Vaccine Type, 2026–2035 ($ Million) 

2. Global Pneumococcal Conjugate Vaccines Market Research and Analysis by Region, 2026–2035 ($ Million) 

3. Global Pneumococcal Polysaccharide Vaccines Market Research and Analysis by Region, 2026–2035 ($ Million) 

4. Global Pneumococcal Vaccine Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

5. Global Conjugate Vaccine Technology Market Research and Analysis by Region, 2026–2035 ($ Million) 

6. Global Polysaccharide Vaccine Technology Market Research and Analysis by Region, 2026–2035 ($ Million) 

7. Global Pneumococcal Vaccine Market Research and Analysis by End User, 2026–2035 ($ Million) 

8. Global Pneumococcal Vaccine for Hospitals Market Research and Analysis by Region, 2026–2035 ($ Million) 

9. Global Pneumococcal Vaccine for Pediatric Clinics Market Research and Analysis by Region, 2026–2035 ($ Million) 

10. Global Pneumococcal Vaccine for Adult Vaccination Centres Market Research and Analysis by Region, 2026–2035 ($ Million) 

11. Global Pneumococcal Vaccine for Public Immunisation Programs Market Research and Analysis by Region, 2026–2035 ($ Million) 

12. Global Pneumococcal Vaccine for Pharmacies / Retail Vaccination Market Research and Analysis by Region, 2026–2035 ($ Million) 

13. Global Pneumococcal Vaccine Market Research and Analysis by Region, 2026–2035 ($ Million) 

14. North America Pneumococcal Vaccine Market Research and Analysis by Country, 2026–2035 ($ Million) 

15. North America Pneumococcal Vaccine Market Research and Analysis by Vaccine Type, 2026–2035 ($ Million) 

16. North America Pneumococcal Vaccine Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

17. North America Pneumococcal Vaccine Market Research and Analysis by End User, 2026–2035 ($ Million) 

18. Europe Pneumococcal Vaccine Market Research and Analysis by Country, 2026–2035 ($ Million) 

19. Europe Pneumococcal Vaccine Market Research and Analysis by Vaccine Type, 2026–2035 ($ Million) 

20. Europe Pneumococcal Vaccine Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

21. Europe Pneumococcal Vaccine Market Research and Analysis by End User, 2026–2035 ($ Million) 

22. Asia-Pacific Pneumococcal Vaccine Market Research and Analysis by Country, 2026–2035 ($ Million) 

23. Asia-Pacific Pneumococcal Vaccine Market Research and Analysis by Vaccine Type, 2026–2035 ($ Million) 

24. Asia-Pacific Pneumococcal Vaccine Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

25. Asia-Pacific Pneumococcal Vaccine Market Research and Analysis by End User, 2026–2035 ($ Million) 

26. Rest of the World Pneumococcal Vaccine Market Research and Analysis by Region, 2026–2035 ($ Million) 

27. Rest of the World Pneumococcal Vaccine Market Research and Analysis by Vaccine Type, 2026–2035 ($ Million) 

28. Rest of the World Pneumococcal Vaccine Market Research and Analysis by Technology Platform, 2026–2035 ($ Million) 

29. Rest of the World Pneumococcal Vaccine Market Research and Analysis by End User, 2026–2035 ($ Million) 

1. Global Pneumococcal Vaccine Market Share by Vaccine Type, 2025 Vs 2035 (%) 

2. Global Pneumococcal Conjugate Vaccines Market Share by Region, 2025 Vs 2035 (%) 

3. Global Pneumococcal Polysaccharide Vaccines Market Share by Region, 2025 Vs 2035 (%) 

4. Global Pneumococcal Vaccine Market Share by Technology Platform, 2025 Vs 2035 (%) 

5. Global Conjugate Vaccine Technology Market Share by Region, 2025 Vs 2035 (%) 

6. Global Polysaccharide Vaccine Technology Market Share by Region, 2025 Vs 2035 (%) 

7. Global Pneumococcal Vaccine Market Share by End User, 2025 Vs 2035 (%) 

8. Global Pneumococcal Vaccine for Hospitals Market Share by Region, 2025 Vs 2035 (%) 

9. Global Pneumococcal Vaccine for Pediatric Clinics Market Share by Region, 2025 Vs 2035 (%) 

10. Global Pneumococcal Vaccine for Adult Vaccation Centers Market Share by Region, 2025 Vs 2035 (%) 

11. Global Pneumococcal Vaccine for Public Immunisation Programs Market Share by Region, 2025 Vs 2035 (%) 

12. Global Pneumococcal Vaccine for Pharmacies / Retail Vaccination Market Share by Region, 2025 Vs 2035 (%) 

13. Global Pneumococcal Vaccine Market Share by Region, 2025 Vs 2035 (%) 

14. US Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

15. Canada Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

16. UK Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

17. France Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

18. Germany Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

19. Italy Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

20. Spain Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

21. Russia Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

22. India Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

23. China Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

24. Japan Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

25. South Korea Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

26. Australia & New Zealand Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

27. ASEAN Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

28. Rest of Asia-Pacific Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

29. Latin America Pneumococcal Vaccine Market Size, 2025–2035 ($ Million) 

30. Middle East & Africa Pneumococcal Vaccine Market Size, 2025–2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The size of the Pneumococcal Vaccine Market in 2025 is estimated to be around $8.90 billion.
United States holds the largest share in the Pneumococcal Vaccine Market.
Leading players in the Pneumococcal Vaccine Market Includes Pfizer Inc., Merck & Co., Inc., GSK plc, Serum Institute of India Pvt. Ltd., and Walvax Biotechnology Co., Ltd.., among others.
The Pneumococcal Vaccine Market is expected to grow at a CAGR of 5.7% from 2026 to 2035.
Rising prevalence of pneumococcal infections, increasing government immunization programs, and growing awareness about preventive healthcare are driving the Pneumococcal Vaccine Market growth.